MetaCap

Cypherpunk Technologies (CYPH) vs Enanta Pharmaceuticals (ENTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cypherpunk Technologies (CYPH) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, losing 38.2% versus a loss of 40.1%. Over five years, ENTA leads with a -91.7% price change compared with -94.4% for CYPH. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $210.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CYPH-38.16%ENTA-40.14%
+89%+2%-85%
Nov 21, 20251 yearNov 20, 2026
CYPH-93.79%ENTA-89.88%
+50%-28%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CYPH versus ENTA key metrics
MetricCYPHENTA
Share price$1.41$7.62
Market cap$210.15M$222.19M
1-day change-18.02%-4.51%
YTD return+21.55%-51.68%
1-year return-38.16%-40.14%
5-year return-94.45%-91.71%
P/E ratio (TTM)0.67—
EPS (TTM)$2.09$-2.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$63.00M
Revenue growth (YoY)—-3.56%
Net income (latest FY)$4.82M$-68.25M
Operating margin—-99.01%
Net margin—-108.33%
52-week high$4.19$17.15
52-week low$0.491$7.56
Distance from 52-week high-66.35%-55.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+254.61%+186.48%
Average volume15.42M287.81K
Shares outstanding149.04M29.16M
Employees6120
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cypherpunk Technologies

CYPH stock →

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Enanta Pharmaceuticals

ENTA stock →

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

CYPH vs ENTA FAQ

Which is bigger, Cypherpunk Technologies or Enanta Pharmaceuticals?

Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $210.15M for Cypherpunk Technologies (CYPH).

Which stock has performed better over the past year, CYPH or ENTA?

CYPH returned -38.16% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.

Are Cypherpunk Technologies and Enanta Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons